Foundation Invests in Program led by Alloy Therapeutics

The CMT Research Foundation has invested in a program by 82VS, Alloy Therapeutics' venture studio, to develop Antibody Oligonucleotide Conjugate (AOC) therapeutics for CMT (Charcot-Marie-Tooth Disease). 

This project leverages Alloy's novel transferrin receptor (TfR1) antibodies, which enhance oligonucleotide delivery to muscle, brain, and peripheral nerves, addressing key challenges in treating CMT. By improving delivery and efficacy in affected tissues, this approach can potentially create therapies for all types of CMT.  

Alloy Therapeutics and 82VS collaborate with patient advocacy groups to advance treatments, combining scientific innovation with community insights to address unmet needs.

Learn more